Duavee for Women 65 and Older: Caregiver Administration Guidance

What Duavee Is and Why It Is Prescribed for Older Women

Duavee is a combination tablet containing conjugated estrogens (CE) 0.45 mg paired with bazedoxifene (BZA) 20 mg, a selective estrogen receptor modulator (SERM). The FDA approved Duavee in 2013 for two indications in postmenopausal women who still have a uterus: treatment of moderate-to-severe vasomotor symptoms (hot flashes, night sweats) and prevention of postmenopausal osteoporosis.

For women 65 and older, the prescription often reflects one or both of these goals. Hot flashes can persist well into a woman's seventh and eighth decade, disrupting sleep, worsening mood, and reducing quality of life. At the same time, bone loss accelerates sharply after menopause, and approximately 20 percent of women over 65 meet criteria for osteoporosis on DEXA scan, making fracture prevention a genuine clinical priority.

How the SERM-Estrogen Combination Works Differently From Standard HRT

Traditional hormone therapy pairs estrogen with a progestogen to protect the uterus. Duavee replaces the progestogen with bazedoxifene, which blocks estrogen receptors in breast and uterine tissue while allowing estrogen to act on bone, brain, and vasomotor centers. This is why the combination is sometimes called a TSEC (tissue-selective estrogen complex).

The practical implication for caregivers is that a woman taking Duavee should not use any additional progestogen, estrogen, or other SERM without explicit clinician approval. Combining Duavee with extra hormonal products can reduce BZA's endometrial protection and increase cancer risk.

What the Clinical Evidence Shows

The SMART (Selective estrogens, Menopause, And Response to Therapy) trial program is the primary evidence base. In SMART-1, CE 0.45 mg / BZA 20 mg produced endometrial atrophy rates comparable to placebo over 24 months, with no cases of endometrial hyperplasia detected in more than 1,500 women studied. The SMART-2 trial demonstrated statistically significant reductions in weekly moderate-to-severe hot flash frequency versus placebo. The SMART-5 trial showed meaningful preservation of lumbar spine and total hip bone mineral density.

It is worth being clear about a limitation: the SMART trials enrolled women primarily in early postmenopause (average age 52-55). Women over 65 were represented, but the subgroup data for this age group were not powered to detect differences in all endpoints independently. Some benefit and risk data in women 65 and older is therefore extrapolated from the broader postmenopausal population, and caregivers should understand that evidence directly in this age group is thinner than in younger postmenopausal women.

Caregiver Administration: Step-by-Step Daily Guidance

Consistent daily administration matters more than timing flexibility with Duavee. The tablet should be swallowed whole, with or without food, at approximately the same time each day. Crushing, chewing, or splitting the tablet is not recommended, because the tablet coating affects both drug release and gastrointestinal tolerability.

Setting Up a Reliable Routine

For women with cognitive impairment or mobility limitations, building Duavee into an existing morning or evening routine reduces missed doses. A pill organizer, a phone alarm set by the caregiver, or a blister-pack calendar from the pharmacy all work equally well. The key is pairing administration with something the woman already does, such as breakfast or toothbrushing.

If a dose is missed, the woman (or caregiver) should take it as soon as remembered the same day. If the next day has already begun, skip the missed dose and resume the regular schedule. Do not double up. Duavee's prescribing information does not specify a consequence window for missed doses, but consistency across weeks matters for endometrial protection and bone outcomes.

Required Calcium and Vitamin D Supplementation

The FDA label specifically requires concurrent supplementation: 1,200 mg of elemental calcium and 800 IU of vitamin D daily. For older women, this is not optional background advice. In women over 70, the recommended dietary allowance for vitamin D rises to 800 IU, and many are deficient at baseline. Caregivers should check that any existing calcium or vitamin D supplement is counted toward the total, rather than adding on top and inadvertently providing excess calcium, which carries its own cardiovascular concerns.

Calcium carbonate absorbs best with food. Calcium citrate absorbs without food and is preferred in women taking proton pump inhibitors or with achlorhydria, both common in this age group.

What to Do With Other Medications

Older women are frequently taking multiple medications. Two drug interactions deserve caregiver awareness.

CYP3A4 inducers, including rifampin, carbamazepine, phenytoin, and St. John's Wort, increase the metabolism of both CE and BZA, potentially reducing hormone levels and endometrial protection. If any of these are added or removed from the medication list, the prescribing clinician should be notified.

Strong CYP3A4 inhibitors such as ketoconazole may raise estrogen levels. This is less likely to be clinically significant at the doses in Duavee, but it warrants a medication reconciliation conversation at each care visit.

Geriatric-Specific Safety Considerations

Women over 65 face a different risk profile from younger postmenopausal women, and the Beers Criteria published by the American Geriatrics Society flags systemic estrogen as a potentially inappropriate medication in older adults due to concerns about venous thromboembolism, stroke, and hormone-sensitive cancers. Duavee specifically is not separately listed in the Beers Criteria, but its estrogen component places it in this general category of concern.

Venous Thromboembolism and Cardiovascular Risk

The Women's Health Initiative (WHI) established that oral conjugated estrogens increase VTE risk in postmenopausal women. The WHI CE-alone arm reported a hazard ratio of approximately 1.35 for VTE over 7.1 years. BZA itself has SERM-class VTE risk similar to raloxifene. Because Duavee combines both, the net VTE risk in women over 65 is a genuine concern.

Caregivers should watch for sudden unilateral leg swelling, calf pain, shortness of breath, or pleuritic chest pain. These are emergencies. Call 911 rather than waiting for a scheduled appointment.

Women with a personal history of DVT, pulmonary embolism, or inherited thrombophilia (such as Factor V Leiden) should generally not be taking Duavee. If such a history surfaces after the prescription has started, the prescriber needs to be called promptly.

Stroke and Cognitive Risk

Oral estrogen does not appear to protect against dementia when started in women over 65. The WHI Memory Study (WHIMS) found that combined estrogen plus progestin increased dementia risk in women 65 and older, though CE-alone showed a non-significant trend. BZA was not part of WHIMS, and no long-term cognitive data specific to CE/BZA in older women exist. This is an evidence gap caregivers and prescribers should discuss openly before continuing Duavee into a woman's late 60s or 70s.

Stroke risk follows a similar pattern. Caregivers should know the FAST acronym: Face drooping, Arm weakness, Speech difficulty, Time to call 911.

Falls, Fracture, and the Bone Benefit Context

For women whose primary reason for taking Duavee is osteoporosis prevention, the benefit must be weighed against the fact that estrogen does not directly reduce fall risk. In SMART-1, bone mineral density improved, but fracture reduction was not the primary endpoint and the trial was not powered to show it directly. For women 65 and older who have already experienced a fracture or who have T-scores in the osteoporosis range, an anti-resorptive agent with established fracture reduction data, such as alendronate or denosumab, may be more appropriate. Duavee is labeled for prevention, not treatment, of osteoporosis.

A practical caregiver framework for bone-related decisions: if the woman's prescriber has recommended Duavee primarily for bone protection and she is 70 or older, ask explicitly at the next visit whether a bisphosphonate or denosumab would offer greater fracture reduction with a better geriatric safety profile.

Breast Safety Monitoring

SMART-5 data showed that CE/BZA did not increase mammographic breast density compared to placebo at 12 months, and breast tenderness rates were low. This is an advantage over combined estrogen-progestogen therapy, where increases in mammographic density complicate screening interpretation.

Despite this reassuring signal, the estrogen component carries a class-based association with breast cancer in long-term use, particularly when used for more than 5 years. Caregivers should ensure the woman attends annual mammography per ACOG's breast cancer screening guidance. Report new breast lumps, nipple discharge, or skin changes to the clinician without delay.

Pregnancy, Lactation, and Contraception: Required Section

Duavee is contraindicated in pregnancy. This is stated plainly in the FDA prescribing information. Conjugated estrogens are classified under the updated PLLR (Pregnancy and Lactation Labeling Rule) as contraindicated in pregnancy because fetal exposure to exogenous estrogens has been associated with congenital abnormalities in animal studies, and because estrogen/SERM combinations have not been studied in human pregnancy.

In postmenopause, pregnancy is by definition not possible, so for the vast majority of women 65 and older taking Duavee, this section is a formality. However, for a small number of women in their early 60s who have not had confirmed menopause (defined as 12 consecutive months without menses), pregnancy remains biologically possible, though exceedingly rare. If any ambiguity about menopausal status exists, the prescriber should confirm FSH and estradiol levels before initiating Duavee.

Bazedoxifene carries specific reproductive toxicity signals in animal data. Its SERM activity means it could theoretically affect fetal development through estrogen-receptor-mediated pathways.

Duavee is also contraindicated in lactation. Estrogens are known to reduce milk supply, and both CE and BZA are expected to transfer into breast milk based on pharmacokinetic class effects, though direct lactation transfer data for BZA specifically are limited. The prescribing label advises against use in breastfeeding women.

For women in their early 60s who are not yet confirmed postmenopausal and who are sexually active, a non-hormonal contraceptive method should be used if Duavee is prescribed off-label or during the transition. The prescribing clinician should document menopausal status clearly.

Who Duavee Is Right For (and Who It Is Not)

Women Who May Benefit

Duavee makes clinical sense for a postmenopausal woman 65 or older who has a uterus, continues to experience moderate-to-severe hot flashes that disrupt sleep or daily function, cannot tolerate or prefers to avoid a separate progestogen, has concerns about mammographic density with combined HRT, or is in the early stages of bone loss (osteopenia on DEXA) and has not yet required a bisphosphonate.

Women who did not tolerate progestogen due to mood symptoms, bloating, or bleeding may find that Duavee's BZA-based endometrial protection is better tolerated, because BZA has no progestogenic activity and does not cause the withdrawal bleeding associated with cyclic progestogen regimens.

Women Who Should Not Take Duavee

Duavee is contraindicated or generally inappropriate for women with a personal history of breast cancer or estrogen-receptor-positive cancer, active or recent VTE or arterial thromboembolism, unexplained vaginal bleeding, liver disease or impaired liver function, known hypersensitivity to CE or BZA, and for women who are pregnant or breastfeeding.

Women over 65 with multiple cardiovascular risk factors (uncontrolled hypertension, diabetes, hyperlipidemia, current smoking, prior stroke) should have a careful benefit-risk discussion. The North American Menopause Society's 2023 Menopause Hormone Therapy Position Statement notes that for women more than 10 years past menopause or over age 60, the risks of initiating hormone therapy generally outweigh benefits for cardiovascular outcomes, though this does not eliminate all use in this group when symptoms are significant.

Women already being treated for osteoporosis with a bisphosphonate or denosumab do not need Duavee for bone purposes. Adding it solely for bone benefit in that context is not supported by evidence.

Monitoring Schedule for Caregivers to Track

Regular monitoring is part of safe long-term use. Caregivers who accompany the woman to appointments or manage her health records should ensure the following are completed on schedule.

At every visit: blood pressure check, review of any new vaginal bleeding or spotting (this is abnormal in a postmenopausal woman and requires prompt evaluation), and medication reconciliation.

Annually: clinical breast exam, mammography per ACOG guidance, pelvic exam if indicated, and discussion of whether continued Duavee use is still appropriate given the woman's current health status.

As clinically indicated: fasting lipid panel (estrogens and SERMs both affect lipid metabolism; CE raises HDL and triglycerides, while BZA has a neutral-to-mildly favorable lipid profile), liver function tests if symptoms of hepatic dysfunction appear, and DEXA scan every 1-2 years if bone protection is a primary indication.

The Menopause Society recommends annual reassessment of the indication, benefit-risk balance, and planned duration for all hormone therapies. For women over 65, this reassessment should be documented in the medical record and should include an explicit conversation about the planned stop date or continuation criteria.

When Caregivers Should Call the Clinician Immediately

Some changes require same-day or emergency contact. Do not wait for a scheduled appointment if the woman develops any of the following:

Sudden new leg swelling or calf pain (possible DVT), sudden shortness of breath or chest pain (possible pulmonary embolism), new-onset severe headache or vision changes (possible stroke or cerebrovascular event), unexpected vaginal bleeding or spotting (requires endometrial evaluation), new breast lump or skin dimpling, yellowing of the skin or eyes (possible hepatic dysfunction), or a new prescription for rifampin, carbamazepine, or another strong CYP3A4 inducer from a different prescribing clinician.

For emergencies (sudden neurological symptoms, chest pain, severe shortness of breath), call 911 first, then notify the prescribing clinician.

Stopping Duavee: What Caregivers Need to Know

The Menopause Society does not endorse an arbitrary 5-year maximum for all hormone therapies, but it does recommend that duration be individualized based on ongoing symptom burden, bone health status, and evolving risk factors. For women over 65, the conversation about stopping Duavee should happen at every annual review.

Stopping does not need to be tapered in the way that antidepressants or corticosteroids do. However, some women experience a return of hot flashes after stopping, which can be significant if symptoms were severe before starting. The prescribing clinician can discuss whether a gradual dose reduction is preferable to abrupt discontinuation for that individual.

After stopping, bone density protection from Duavee wanes. If the woman's bone health was a primary reason for treatment, a transition plan to a bisphosphonate or other anti-resorptive agent should be in place before discontinuation.